Skip to main content
. 2018 May 8;49(6):1464–1470. doi: 10.1161/STROKEAHA.117.018825

Figure 3.

Figure 3.

Cost-effectiveness plane at 20 years of left atrial appendage closure (LAAC) vs warfarin, LAAC vs dabigatran, and LAAC vs apixaban. QALY indicates quality-adjusted life year.